Erratum: DUET: A phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS (Journal of the American Society of Nephrology (2018) 29 (2745–2754) DOI: 10.1681/ASN.2018010091);DUET: A phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS

Journal of the American Society of Nephrology

Volumn 29, Issue 11, 2018, Pages 2745-2754

  Trachtman, Howard ^a   Nelson, Peter ^b   Adler, Sharon ^c   Campbell, Kirk N ^d   Chaudhuri, Abanti ^e   Derebail, Vimal Kumar ^f   Gambaro, Giovanni ^g   Gesualdo, Loreto ^h   Gipson, Debbie S ⁱ   Hogan, Jonathan ^j   Lieberman, Kenneth ^k,l   Marder, Brad ^m   Meyers, Kevin Edward ^n,o   Mustafa, Esmat ^p   Radhakrishnan, Jai ^q   Srivastava, Tarak ^r,s   Stepanians, Miganush ^t   Tesar, Vladimír ^u,v   Zhdanova, Olga ^a   Komers, Radko ^w  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e STANFORD UNIVERSITY   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^h POLICLINICO   (Italy)

ⁱ UNIVERSITY OF MICHIGAN   (United States)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^l HACKENSACK MERIDIAN SCHOOL OF MEDICINE   (United States)

^m Clinical Research at Colorado Kidney Care   (United States)

ⁿ CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^o UNIVERSITY OF PENNSYLVANIA   (United States)

^p Arizona Kidney Disease and Hypertension Center   (United States)

^q Och Spine at New York Presbyterian Hospitals   (United States)

^r CHILDREN S MERCY HOSPITAL   (United States)

^s UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^t Johnson and Johnson R D   (United States)

^u CHARLES UNIVERSITY   (Czech Republic)

^v CHARLES UNIVERSITY   (Czech Republic)

^w Retrophin Inc ^*  (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; IRBESARTAN; SPARSENTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ENDOTHELIN A RECEPTOR ANTAGONIST;

ADOLESCENT; ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CHILD; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; ESTIMATED GLOMERULAR FILTRATION RATE; FATIGUE; FEMALE; FOCAL GLOMERULOSCLEROSIS; HEADACHE; HUMAN; HYPERKALEMIA; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MUSCLE SPASM; NAUSEA; NOSE OBSTRUCTION; OPEN STUDY; ORTHOSTATIC HYPOTENSION; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; REMISSION; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URINE SAMPLING; VOMITING; CLINICAL TRIAL; DOSE RESPONSE; MIDDLE AGED; MULTICENTER STUDY; PROTEINURIA; URINE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CHILD; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENDOTHELIN A RECEPTOR ANTAGONISTS; FEMALE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; IRBESARTAN; MALE; MIDDLE AGED; PROTEINURIA; YOUNG ADULT;

EID: 85055841083     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2019010051     Document Type: Erratum

References (31)

1. D'Agati VD, Kaskel FJ, Falk RJ: Focal segmental glomerulosclerosis. N Engl J Med 365: 2398-2411, 2011
2. Zand L, Glassock RJ, De Vriese AS, Sethi S, Fervenza FC: What are we missing in the clinical trials of focal segmental glomerulosclerosis? Nephrol Dial Transplant 32[Suppl 1]: i14-i21, 2017
3. Messina M, Gallo E, Mella A, Pagani F, Biancone L: Update on the treatment of focal segmental glomerulosclerosis in renal transplantation. World J Transplant 6: 54-68, 2016
4. Reiser J, Nast CC, Alachkar N: Permeability factors in focal and segmental glomerulosclerosis. Adv Chronic Kidney Dis 21: 417-421, 2014
5. Rosenberg AZ, Naicker S, Winkler CA, Kopp JB: HIV-associated nephropathies: Epidemiology, pathology, mechanisms and treatment. Nat Rev Nephrol 11: 150-160, 2015
6. Korbet SM: Treatment of primary FSGS in adults. J Am Soc Nephrol 23: 1769-1776, 2012
7. Kiffel J, Rahimzada Y, Trachtman H: Focal segmental glomerulosclerosis and chronic kidney disease in pediatric patients. Adv Chronic Kidney Dis 18: 332-338, 2011
8. Saran R, Li Y, Robinson B, Ayanian J, Balkrishnan R, Bragg-Gresham J, et al.: US Renal Data System 2014 Annual Data Report: Epidemiology of kidney disease in the United States. Am J Kidney Dis 66: Svii, S1-S305, 2015
9. Spino C, Jahnke JS, Selewski DT, Massengill S, Troost J, Gipson DS: Changing the paradigm for the treatment and development of new therapies for FSGS. Front Pediatr 4: 25, 2016
10. Alexopoulos E, Stangou M, Papagianni A, Pantzaki A, Papadimitriou M: Factors influencing the course and the response to treatment in primary focal segmental glomerulosclerosis. Nephrol Dial Transplant 15: 1348-1356, 2000
11. Cattran DC, Rao P: Long-termoutcome in children and adults with classic focal segmental glomerulosclerosis. Am J Kidney Dis 32: 72-79, 1998
12. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group: KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2: 135, 2012
13. Sethna CB, Gipson DS: Treatment of FSGS in children. Adv Chronic Kidney Dis 21: 194-199, 2014
14. Pullen N, Fornoni A: Drug discovery in focal and segmental glomerulosclerosis. Kidney Int 89: 1211-1220, 2016
15. Kohan DE, Pritchett Y, Molitch M, Wen S, Garimella T, Audhya P, et al.: Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J AmSoc Nephrol 22: 763-772, 2011
16. Kohan DE, Barton M: Endothelin and endothelin antagonists in chronic kidney disease. Kidney Int 86: 896-904, 2014
17. Komers R, Plotkin H: Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease. Am J Physiol Regul Integr Comp Physiol 310: R877-R884, 2016
18. de Zeeuw D, Coll B, Andress D, Brennan JJ, Tang H, Houser M, et al.: The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. JAmSoc Nephrol 25: 1083-1093, 2014
19. Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, et al.: ASCEND Study Group: Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 21: 527-535, 2010
20. A receptor antagonists reduce blood pressure in experimental hypertension. J Pharmacol Exp Ther 309: 275-284, 2004
21. Komers R, Gipson DS, Nelson P, Adler S, Srivastava T, Derebail VK, et al.: Efficacy and safety of sparsentan compared with irbesartan in patients with primary focal segmental glomerulosclerosis: Randomized, controlled trial design (DUET). Kidney Int Rep 2: 654-664, 2017
22. Gadegbeku CA, Gipson DS, Holzman LB, Ojo AO, Song PX, Barisoni L, et al.: Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int 83: 749-756, 2013
23. Troost JP, Trachtman H, Nachman PH, Kretzler M, Spino C, Komers R, et al.: An outcomes-based definition of proteinuria remission in focal segmental glomerulosclerosis. Clin J AmSoc Nephrol 13: 414-421, 2018
24. Dhaun N, MacIntyre IM, Kerr D, Melville V, Johnston NR, Haughie S, et al.: Selective endothelin-A receptor antagonismreduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension 57: 772-779, 2011
25. Rüster C, Wolf G: Angiotensin II as a morphogenic cytokine stimulating renal fibrogenesis. J Am Soc Nephrol 22: 1189-1199, 2011
26. Wennmann DO, Hsu HH, Pavenstädt H: The renin-angiotensin-aldosterone system in podocytes. Semin Nephrol 32: 377-384, 2012
27. Buelli S, Rosanò L, Gagliardini E, Corna D, Longaretti L, Pezzotta A, et al.: β-arrestin-1 drives endothelin-1-mediated podocyte activation and sustains renal injury. J Am Soc Nephrol 25: 523-533, 2014
28. Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC; Toronto Glomerulonephritis Registry Group: Focal and segmental glomerulosclerosis: Definition and relevance of a partial remission. J Am Soc Nephrol 16: 1061-1068, 2005
29. Gipson DS, Trachtman H, Kaskel FJ, Greene TH, Radeva MK, Gassman JJ, et al.: Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int 80: 868-878, 2011
30. Genovese G, Tonna SJ, Knob AU, Appel GB, Katz A, Bernhardy AJ, et al.: A risk allele for focal segmental glomerulosclerosis in African Americans is located within a region containing APOL1 and MYH9. Kidney Int 78: 698-704, 2010
31. Woroniecki RP, Ng DK, Limou S, Winkler CA, Reidy KJ, Mitsnefes M, et al.: Renal and cardiovascular morbidities associated with APOL1 status among African-American and Non-African-American children with focal segmental glomerulosclerosis. Front Pediatr 4: 122, 2016